LHE Title LHE Logo

About

Liverpool Health Economics (LHE) is a research and consultancy centre within the University of Liverpool Management School. It consists of a core team and associates, with both academic and practical expertise in health economics, research, modelling, statistics, systematic reviews and management across the health and social care sector.

Our reputation is built upon promoting the best possible outcomes with available resources through the evaluation of costs and benefits of health and social care interventions. Our research aims to make a real difference by improving health through ensuring best use of scarce resources without sacrificing quality or compassion.

More specifically, our aim is to continue to develop and apply health economic tools to improve health care and population health globally. Moreover, we wish to make available a body of expertise in health economics and provide an excellent service to our clients.

Underpinned with an academic base, LHE has initiated, developed and delivered a vast amount of projects in collaboration with local, national and international health and social care sectors, the pharmaceutical industry and other related organisations. The broad nature of these projects have been conducted to inform health policy, enabling innovations and implementation of new health interventions, whilst supporting health and social care decision-making at all levels across the UK and overseas.

science Ulms2 plot

Team

The multi-disciplinary nature of the LHE team means there is an appropriate mix of skills that can be drawn upon and utilised to meet the diverse needs of new and existing clients. In addition, our close links to NHS policy makers and other academic groups ensures credibility along with an excellent track record of working in partnership with colleagues across the public, private and third sector.

Members and collaborators of the Liverpool Health Economics team include:

Dr Alan Haycox BA MA PhD

Alan Portrait Reader in Health Economics, Director of LHE

Alan is an internationally recognised Health Economist, expert advisor to NHS, pharmaceutical industry and a number of regulatory and funding authorities. In one of his previous roles, he was employed as Regional Health Economist in the North West Regional Health Authority, assisting in the prioritisation of healthcare provision to the population of the North West. He is a member of the NICE Technology Appraisals Committee and he is a founder of the Liverpool Technology Assessment Review (TAR) LHE. He specialises in pharmacoeconomic evaluation and has worked with an extensive range of pharmaceutical companies, guiding the economic evaluation of the new pharmaceutical products. His work is widely published and he is also a reviewer for a range of high profile journals.

Mark Parker BA MSc

Mark Portrait Senior Research Fellow, PhD Candidate

Mark is a Senior Economic modeller for LHE and the Liverpool Cancer Trials Unit, and he is a Technical Director of Evaluate Econ Ltd. These roles have mostly involved developing models and evidence based messages for a wide range of disease areas for global value dossiers and HTA submissions to NICE, SMC and CVZ, along with internal decision-making. He has experience in a vast range of disease areas and population modelling, with a strong educational background in economics, software development, distributed systems and computation, and Artificial Intelligence. This training, education and experience provide the means to apply the world's most advanced techniques to solve complex problems in a methodical, transparent and comprehensible way, with a core focus on knowledge transfer and developing evidence based value arguments for Health Technology Assessment.

Simon Leigh BSc MSc

Simon Portait Research Fellow

Simon completed an MSc in Health Economics at the University of York, and has been a member of LHE since 2012. He has provided health-economic input into areas such as urology, cardiology, alcohol and reproductive services and hepatology; however his main area of research concerns the economics of maternal, neonatal and perinatal health. Simon is involved in a number of clinical trials, primarily evaluating interventions to improve outcomes during gestation, labour and delivery. These include the prevention of pre-term birth and the management of pre-eclampsia. Simon has recently modelled the incidence and implications of asphyxia-related cerebral palsy in the UK, arising solely as a result of substandard care, in addition to evaluating the extent of hepatitis C infection in Europe, estimating the long-term survival, quality of life and resource impact of the disease, and working on strategies to improve access to treatment in high-risk groups.

Paul Granby BSc MSc

Paul Portait Research Fellow

Paul completed an MSc in Health Economics at the University of York, and has also been a member of LHE since 2012. Paul's main areas of research are in cardiology (specifically aortic services), hepatology and alcohol services. Paul coordinates and lectures on the undergraduate module in health economics at the management school and also contributes to a number of NIHR and RfPb trials, as well as sitting on the Liverpool cancer trials unit (LCTU) health technologies advisory committee. Paul's current research concerns evaluating the extent of hepatitis C infection in Europe, budget impact analysis for proposed treatments, and performing a systematic review of the disease in Scandinavia.

Brendan Collins HECert BSc MSc PGCert

Brendan Research Fellow, PhD Candidate

Brendan has been working as a health economist and modeller for over seven years. He has worked in the national health service, academia and for local authorities, with a focus on public health and health intelligence in the North West of England and in London. He specialises in assessing health inequalities and evaluating public health interventions. He has been involved in several service redesign projects around CVD, mental health and health visitors. He has experience of economic modelling using TreeAge and Excel VBA, as well as demand and capacity modelling using SIMUL8 Scenario Generator. He is currently completing his PhD on the topic of economic evaluation as applied to public health funded treatment of addiction. He teaches at undergraduate and Masters levels at Liverpool and London South Bank University. He sits as an expert member on a NICE Public Health Advisory Committee.

Antony P. Martin BSc MSc

Antony Portait Research Fellow

Since joining LHE, Antony has made significant contributions towards several innovative projects. He completed his BSc in Economics at the University of Liverpool and his MSc in Health Economics at City University London, funded by a scholarship from the NIHR. Previously, he worked for a leading HEOR consultancy company, gaining experience in cost-effectiveness model adaptations, budget impact models, systematic literature reviews and health technology assessment reports. Antony has experience working within a range of health areas such as alcoholism, hepatitis C, HIV/AIDS, pre-term birth, and he has developed a keen interest in health policy debate. He has also developed an international profile after spending extended periods of time studying and working abroad in Brazil, Hong Kong and Peru.

Andrew T. Hall BSc

Andy Portait Honorary Research Fellow

Andrew completed his BSc in Economics at the University of Liverpool, and is a valued a member of LHE. He has made significant contributions towards several innovative projects and gained experience in cost-effectiveness model adaptations, comprehensive literature reviews, and applying computer programming to quantitative research projects. Andrew has experience working within a range of health areas, including alcoholism, hepatitis C, COPD and he is developing a keen interest in health economic modelling.

Services

science With increasing demands being made on limited resources, it is crucial for commissioners and providers to be able to demonstrate maximum value for money by ensuring not only clinical effectiveness but also the cost effectiveness of health and social care interventions.

Taking a flexible, collaborative approach, LHE aims to provide an accessible, adaptable service that meets the needs of all clients, to ensure our health economic contributions can be both understood and used in a meaningful way by professionals from all vocations.

We provide research, bespoke consultancy, specialist advice, professional development courses, knowledge sharing forums, training events and workshops to support best practice and evidence-based decision making. This spans:

  • Clinical trials
  • Cost-effectiveness and cost-benefit studies
  • Economic evaluation
  • Health modelling
  • Feasibility studies
  • Budget impact and disease modelling
  • Systematic literature reviews and meta-analysis
  • Health technology and market access appraisals
  • Survival analysis
  • Publications and Infographics

The team at LHE have successfully gained knowledge in a wide range of therapeutic areas. A number of projects undertaken have enabled LHE to significantly impact and influence national and international health policy by optimising NHS decision-making on drug adoption and other clinical interventions, as well as disseminating HTA expertise and application around the globe. The scope of projects are both geographical and organisational, spanning the UK NHS, European, African and Asian healthcare systems, moreover, the pharmaceutical industry.

Please contact us at LHE to find out how we can help.

Testimonials

"Honoured to collaborate sharing knowledge and expertise"

President,
International Society for Pharmacoeconomics and Outcomes Research.

"Thank you very much for giving me the opportunity to take part in such interesting training"

Senior Health Economist, Poland.

"Thank you again for all your hard work and we look forward to working with you again in the future"

International Sleep Disorders Forum

"We would like to take this opportunity to thank you for reviewing proposals for the Public Health Research programme during the past year"

NIHR Programme Manager

"I am happy to attest to the fundamental and significant impact that the Liverpool Health Economics unit has had upon the development of Health research and policy throughout South East Asia, especially in Indonesia and Taiwan... Dr Haycox has been preeminent in helping to develop research and evidence based policies to facilitate the move towards systems of Universal healthcare coverage throughout the region... (he) is held in the highest regard by eminent academics and health professionals throughout South East Asia"

Director (Asia, Middle East and Africa),
Novartis

"We see Liverpool as being a preeminant research based group that has significantly influenced health research and policy in Egypt...The role of the Liverpool group (LHE) in contributing to the overall development of health economics in Egypt can therefore not be overstated"

Minister's Technical Office,
Ministry of Health & Population, Arab Republic of Egypt

"The research undertaken at Liverpool has greatly influenced the development of health services in Egypt over the past ten years...the research presentations in Egypt by Dr. Haycox have been immensely beneficial both in terms of direct skill transference but, perhaps more importantly, in generating a strong interest in Health Economic research amongst the medical research team"

Central Administration of Pharmaceutical Affairs General Directorate of Hospital Pharmacy,
Ministry of Health & Population, Arab Republic of Egypt

"I am delighted to submit such a testimonial in recognition of the extraordinary contribution that the Liverpool team have made to the development of Health Research and policy in Indonesia both in the fields of Health Economics and Outcomes Research...the Liverpool group (LHE) have substantially contributed to both practical analyses and methodological developments in Indonesia over many years"

Center for Health Economics and Policy Analysis (CHEPS),
University of Indonesia

Current Research

Some of our current research projects are listed below:
  • Cost effectiveness analysis comparing Foley catheterisation and oral Misoprostol for the induction of labour in pre-eclamptic pregnancy.
  • Comparing the cost-effectiveness of Arabin pessary, cervical cerclage and progesterone for the prevention of pre-term birth.
  • Assessing the utility of alcohol-related A&E admissions as a predictor of long-term hepatic complications and future NHS reource utilisation.
  • To investigate whether some patients with excellent responses to the treatment of chronic myeloid leukaemia (CML) with tyrosine kinase inhibitor therapy are being over-treated and can remain well on a lower dose of treatment or without treatment at all.
  • Cost effectiveness analysis of Plerixafor for first line stem cell mobilisation: individual patient costing analysis.
  • The Primary Care Home – Whole System Transformation in Warrington. Prospects for healthcare in the future, moving from an acute to more of a primary care setting.
Ulms2 science plot

Selected International Presentations

  • Nov 2013 - Advisory Board, Novartis, Ophthalmology, Zurich, Switzerland.
  • Oct 2013 - 6th Asia Pacific Future Trends Workshop.
  • June 2013 - International Drug Pricing and Pharmacoeconomics, Beijing, China.
  • June 2013 - International HTA Workshop, Taipei, Taiwan.
  • April 2013 - 2nd META FTV, Dubai, Saudi Arabia.
  • Nov 2012 - ‘Risk sharing-lessons for South Korea from the UK. Presentation to Senior Policymakers at the University of Seoul Health Economics Conference.
  • Oct 2012 - ‘Evaluating End of Life Care-the economic perspective’. – Presentation at World Health Forum, Sao Paulo, Brazil.
  • Oct 2012 - ‘Workshop and Seminar presentations at CEESTAC conference Krakow, Poland.
  • Aug 2012 - ‘Optimising healthcare resource allocation-the use of HTA’ –Presentation at 5th Asia Pacific Future Trends (Pricing &Reimbursement) Workshop, Taipei, Taiwan.
  • June 2012 - Chair, Parkinsons Disease Advisory Board Dublin, Ireland.
  • April 2012 - ‘The NICE approach to HTA’ – presentation to faculty of Management, University of Budapest , Hungary.
  • April 2012 - ‘Economic Evaluation Of End Of Life Care’ – Presentation at Future Trends Workshop, Muscat, Oman.
  • April 2012 ‘NICE and end of life care’ Presentation at First Malaysian Pharmacoeconomic And Outcome Research Conference, Kuala Lumpa, Malaysia.
  • March 2012 - ‘Economic Evaluation Of End Of Life Care’ – Presentation at International Pricing Workshop, Sharm El Sheik, Egypt.
  • March 2012 - ‘Health Technology Assessment In Practice’ Presentation at The Managed Introduction Of New Medicines, Slovenia.
  • Dec 2011 - Current And Future Pricing And Reimbursement Of Pharmaceutical Products – Pricing Workshop, Cairo, Egypt.
  • Oct 2011 - Chairman Expert Advisory Board On Health Economics In Decision Making, Shire Pharmaceuticals, Manchester, UK.
  • Sept 2011 - Chair – Healthcare And Public Management Stream 1th Annual Association Of Management Conference, National College Of Ireland, Dublin, Ireland.
  • Sept 2011 - Health Technology Assessment – The UK Perspective. Asia Pacific Future Trends Workshop, Jakarta, Indonesia.
  • July 2011 - Workshop Leader, Expert Advisory Board In Parkinsons Disease. GSK London.
  • June 2011 - Workshop Leader, Asthma Expert Advisory Board, GSK, London, UK.
  • June 2011 - Workshop Leader, International Health Technology Assessment Workshop – Structural Excellence, Taipai, Taiwan.
  • Dec 2010 - Health Economics Of Testosterone Treatment, BSP Andrology Workshop, London, UK.
  • Nov 2010 - Workshop “Benefit Analysis In Diabetes Care.” Central And Eastern Europe Diabetes Association, Bratislava, Slovakia.
  • Nov 2010 - Keynote Presentation “Remuneration Issues In Cancer.” ISPOR, Prague, Czech Republic.
  • Oct 2010 - Keynote Presentation “Use Of Mapping Processes In Obtaining Utility Estimates In Quality Of Life Research,” ISOQOL, London, UK.
  • Sept 2010 - Keynote Presentation “Application Of Health Economic Evaluation In The Asia-Pacific Region.” ISPOR, Phuket, Thailand.
  • Sept 2010 - Round Table Discussion On The Development Of Health Technology Assessment In Asia. Thailand Health Department. Bangkok, Thailand.
  • Aug 2010 - Presentation “Applying Health Economic Principles In Norway.” Norwegian Institute Of Health Technology Assessment, Norway.
  • May 2010 - Presentation “Health Technology Assessment For UAE In The Gulf States.” Third Gulf Healthcare Summit, Dubai, UAE.
  • May 2010 - Presentation “Optimising The Introduction Of New Drugs Through Europe.” Mario Negri Institute Of Pharmacological Research, Milan, Italy.
  • March 2010 - Workshop “Health Economics For Oncologists”, Turkish Society Of Clinical Oncology, Anatalya, Turkey.
  • March - 2010 Round Table Discussion With Turkish Ministry Of Health On The Development Of Health Technology Assessment In Turkey.
  • Feb 2010 - Workshop On Optimising The Use Of Healthcare Resources In Resource Limited Environment. Piperska Alliance, Berlin, Germany.
  • Nov 2009 - One-Day Workshop “Principles Of Health Economics”. Novo Nordisk, Liraglutide Advisory Board Members’ Meeting, 26-27 November 2009, Prague, Czech Republic.
  • Oct 2009 - Workshop Leader On Two-Day Health Technology Assessment Workshop For The European Association Of Clinical Pharmacology &Therapeutics, Kapadokya, Turkey.
  • Sept 2009 - One-Day Workshop “An Introduction To Health Economics”. Wirral PCT, Presented In-House ULMS, Wirral, UK.
  • Sept 2009 - “Chronic Insomnia: Healthcare Consumption”. Attendance At And Presentation For “The Burden Of Insomnia” Sanofi Aventis Expert Advisory Board Meeting, New York, US.
  • July 2009 - One-Day Workshop “Understanding Health Economics”. Training Day For Medical Writers, Oxford, UK.
  • July 2009 - Two-Day Workshop “Understanding Health Economics”. Piperska Alliance, Glasgow, UK.
  • May 2009 - Presentation “The Changing Healthcare Environment In Europe. Implications For Economic Evaluation In The Future”. Wolters Kluwer Health, Madrid, Spain.
  • Feb 2009 - Presentation “Economic Evaluation In Chronic Diseases”. GlaxoSmithKline, Haydock Racecourse, UK.
  • Dec 2008 - Presentation “Current Perspectives And Future Challenges From The UK”. Presentation To Senior Clinicians. Warsaw, Poland.
  • Nov 2008 - Presentation “International Cooperation In Enhancing Evidence-Based Healthcare”. Krakow, Poland.

  • Nov 2008 - Presentation “Supporting Clinical Decision-Making In Diabetes”. Presentation To Senior Clinicians And Academic Diabetologists. Warsaw, Poland.
  • June 2008 - Presentations “Supporting Clinical Decision-Making: The Role Of NICE” And “HTA In Practice: Lessons From The UK“ Expert Workshops, British Polish Health Forum. Warsaw And Katowice, Poland (Under The Auspices Of The Polish Chamber Of Commerce).
  • May 2008 - Presentation “Supporting Clinical Decision-Making In Diabetes: The Role Of HTA”. Presentation To Senior Clinicians And Academic Diabetologists. Warsaw, Poland.
  • April 2008 - Two-Day Workshop Leader At The 1st ISPOR (International Society For Pharmacoeconomics and Outcomes Research) International Summer School, Antalya, Turkey.
  • Jan 2008 - Two Day Workshop “Rational Use Of Medicines Including New Expensive Medicines”. Presentation To Senior Pharmacologists, Karolinska Institute, Stockholm, Sweden.
  • Nov 2007 - Presentation “Costs And Outcomes: Areas Of Knowledge And Areas Of Ignorance”. At Health Economics Of Palliative Care: Research Methods &Funding Applications. Kings College, London (Funded By The Open Society Institute).
  • April 2007 - Presentation “Economic Modelling &Reimbursement”. Janssen Cilag, Paris, France.
  • Sept 2006 - The Art Of Good Sleep At The 4th International Sleep Disorders Forum, Rome, Italy.
  • Jan 2006 - Pharmacoeconomics In Europe, Sankyo Pharma, Munich, Germany.
  • Nov 2005 - Workshop Leader At The 4th International Workshop On Pharmacoeconomics &Pharmacoepidemiology. European Association For Clinical Pharmacology &Therapeutics Istanbul, Turkey.
  • Mar 2005 - The Pharmaceutical Marketplace – Key Drivers For The Future. Interlachen Group Summit, Switzerland.
  • Nov 2004 - Workshop Leader At The 2nd International Workshop On Pharmacoeconomics &Pharmacoepidemiology, European Association For Clinical Pharmacology &Therapeutics, Antalya, Turkey.
  • Nov 2003 - Keynote Address ‘NICE – Lessons For Europe’. Centro Italiano Di Solidarietà Di Roma (CEIS) Conference, University Of Rome Tor Vergata, Rome, Italy.
  • June 2003 - Introduction To Pharmacoeconomics. Day-Long Workshop On Pharmacoeconomics At The European Association For Clinical Pharmacology &Therapeutics (EACPT), Istanbul, Turkey.

  • Publications

    Books

  • Walley, T., Haycox, A., Boland, A. ‘Pharmacoeconomics’. Harcourt Health Services, Edinburgh, 2003.
  • Wright, K., Haycox, A., Leedham, I. 'Evaluating Community Care'. Services for people with Learning Difficulties, Open University Press, Buckingham, 1994.
  • Haycox, A. ‘The Costs and Benefits of Community Care; a case study’. Avebury Press, Aldershot, 1994.
  • Book Chapters

  • Haycox A. What Is Cost Minimization Analysis? In: Arnold RJG, Pharmacoeconomics: From Theory to Practice. Florida USA, 2009.
  • Haycox, A., Boland, A., Harris, R. Principles and Practices of Health Economics in Evaluating Oral Health. In: Pine C, Harris R (eds) Community Oral Health, Quintessence, Berlin, 2006.
  • Haycox, A. Healthcare Policy in UK. The Recent Trends CEIS Healthcare Report. University of Rome Tor Vergata, 2004.
  • Mair, FS., Hibbert, D., May, C., Angus, R., Finch, T., Boland, A., O’Connor, J., Haycox, A., Roberts, C., Capewell, S. Problems with implementation – the story of a home telecare trial. In: Whitten P., Cook, D eds. Understanding Health Communications Technologies: A Case Study Approach. San Francisco, Jossey-Bass Inc, 2004.
  • Boardman, A., Hodgson, R., Lewis M., Allen, K., Haycox, A., Unsworth, L. A longitudinal evaluation of two psychiatric in-patient units attached to a community mental health centre; outcomes and costs chapter in emergency psychiatry in a changing world. De Clercqu, M., Andreoli, A., and Lamane, S., (editors), 1999.

  • Haycox, A. ‘Pharmacy Policy and Practice: The Future’. Chapter in ‘Managerial Issues in the Reformed NHS’ (eds. Malek et al) John Wiley and Sons, Chichester, 1993.
  • Wright, K., Haycox, A. ‘Economics and the Care of People with a Mental Handicap’. Chapter in ‘Mental Handicap: Social Science Approaches’, (eds. Hattersley J and Baldwin S). 1990.

  • Peer Reviewed Papers

  • Leigh S, Granby P, Turner M, Wieteska S, Haycox A, Collins B. The Incidence and Implications of Cerebral Palsy Following Avoidable Obstetric Complications: A Preliminary Burden of Disease Study. BJOG: An International Journal of Obstetrics & Gynaecology. 2014 (Accepted for publication)
  • Yip VS. Collins B. Dunne D. Koay MY. Tang JM. Wieshmann H. Fenwick SW. Poston GJ. Malik HZ et al. 2014 Optimal imaging sequence for staging in colorectal liver metastases: Analysis of three hypothetical imaging strategies.European Journal of Cancer 50(5):937-943
  • Collins B. (2013) Using a Survey to Estimate Health Expectancy and Quality-Adjusted Life Expectancy to Assess Inequalities in Health and Quality of Life.(Link) Value in Health 16(4): 599-603.
  • Collins B. (2013) Food hygiene, deprivation, types of premises and rates of gastrointestinal illnesses in the UK.(Link) Public Health Nutrition (in press).
  • Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Haycox A. Personalizing health care: feasibility and future implications. BMC Med, 2013. Aug 13; 11:179.
  • Haycox A. How much should the NHS pay for a QALY? Pharmacoeconomics, 2013. May;31(5):357-9.
  • Malmström RE, Godman BB, Diogene E, Baumgärtel C. Dabigatran- a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol, 2013. 4:39.
  • Haines A, Goldson B, Haycox A, Houten R, Lane S, McGuire J, Nathan T, Perkins E, Richards E and Whittington R. Evaluation of the Youth Justice Liaison and Diversion (YJLD) Pilot Scheme. London, Department of Health, 2012.
  • Davari M, Haycox A, Walley T. Health Care Financing In Iran; Is Privatization A Good Solution? . Iranian J Publ Health, 2012. vol 41 pp 14-23.
  • Davari M, Haycox A, Walley T. The Iranian Health Insurance System; Past Experiences, Present Challenges And Future Strategies.. Iranian J Publ Health 2012. vol 14 pp 1-9.
  • Davari M, Haycox A, Walley T. Pharmaceutical Policy and Market in Iran: past experiences and future challenges . Journal of Pharmaceutical Health Services Research, 2012. vol 2 pp 47-52.
  • Qureshi NA, Neyaz Y, Khoja T, Magzoub MA, Haycox A, Walley T. Effectiveness of three interventions on primary care physicians' medication prescribing in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011 Feb;17(2):172-9. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Magzoub MA, Neyaz Y, Khoja T, Qureshi NA, Haycox A, Walley T. East Determinants of physicians' medication prescribing behaviour in primary care in Riyadh City, Saudi Arabia. Mediterr Health J. 2011 Feb;17(2):160-6. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Khoja T, Neyaz Y, Qureshi NA, Magzoub MA, Haycox A, Walley T. Medication errors in primary care in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011 Feb;17(2):156-9. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Neyaz Y, Khoja T, Qureshi NA, Magzoub MA, Haycox A, Walley T. [Medication prescribing pattern in primary care in Riyadh City, Saudi Arabia] East Mediterr Health J. 2011 Feb;17(2):149-55. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Qureshi NA, Neyaz Y, Khoja T, Magzoub MA, Haycox A, Walley T. Effectiveness of three interventions on primary care physicians' medication prescribing in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011 Feb;17(2):172-9. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.

  • Neyaz Y, Khoja T, Qureshi NA, Magzoub MA, Haycox A, Walley T. East Mediterr Health J. Predictors of quality of medication prescribing in primary care in Riyadh City, Saudi Arabia. 2011 Feb;17(2):167-71. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Magzoub MA, Neyaz Y, Khoja T, Qureshi NA, Haycox A, Walley T. East Determinants of physicians' medication prescribing behaviour in primary care in Riyadh City, Saudi Arabia. Mediterr Health J. 2011 Feb;17(2):160-6. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.

  • Khoja T, Neyaz Y, Qureshi NA, Magzoub MA, Haycox A, Walley T. Medication errors in primary care in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011 Feb;17(2):156-9. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Neyaz Y, Khoja T, Qureshi NA, Magzoub MA, Haycox A, Walley T. [Medication prescribing pattern in primary care in Riyadh City, Saudi Arabia] East Mediterr Health J. 2011 Feb;17(2):149-55. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Qureshi NA, Neyaz Y, Khoja T, Magzoub MA, Haycox A, Walley T. Physicians' medication prescribing in primary care in Riyadh City, Saudi Arabia. Literature review, part 3: prescribing errors. East Mediterr Health J. 2011 Feb;17(2):140-8. Review. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Khoja T, Qureshi NA, Neyaz Y, Magzoub MA, Haycox A, Walley T. Physicians' medication prescribing in primary care in Riyadh City, Saudi Arabia. Literature review, part 2: rational prescribing. East Mediterr Health J. 2011 Feb;17(2):132-9. Review. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Neyaz Y, Qureshi NA, Khoja T, Magzoub MA, Haycox A, Walley T. Physicians’ medication prescribing in primary care in Riyadh City, Saudi Arabia. Literature review, part 1: variations in drug prescribing. Mediterr Health J. 2011 Feb;17(2):126-31. Review. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.

  • Parker M, Haycox A, Graves J. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. Pharmacoeconomics. 2011 Aug;29(8):719-30
  • Godman B, Sakshaug S, Berg C, Wettermark B and Haycox A. Combinations of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):121-9

  • Godman B, Wettermark B, Sakshaug S, Berg C and Haycox A. Differences in the influence of prescribing restrictions; implications for calculating future efficiency savings. In preparation.
  • Garuoliene K, Godman B, Gulbinovic J, Wettermark B and Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Review of Pharmacoeconomics &Outcomes Research. June 2011, Vol. 11, No. 3, Pages 343-349
  • Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C and Haycox A. Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypical are available. Applied Health Economic and Health Policy, 2011. Vol 9; No 2: pp101-110
  • Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. Health Service Research, 2010. Vol 10: pp153.
  • McGinn D, Godman B, Lonsdale J, Way R, Wettermark B and Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: Impact and implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2010. Vol 10; No 1: pp73–85.
  • Sermet C, Andrieu V, Godman B, van Ganse E, Haycox A &Reynier JP. Ongoing Pharmaceutical Reforms in France: Implications for Key Stakeholder Groups. Applied Health Economics and Health Policy, 2010. Vol 8; No 1: pp7-24.
  • Khoja T, Neyaz Y, Qureshi NA, Magzoub MA, Haycox A, Walley T. Medication errors in primary care in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011 Feb;17(2):156-9. Erratum in: East Mediterr Health J. 2011 Mar;17(3):249.
  • Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A and Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Reviews in Pharmacoeconomics, 2009. Vol 9; No1: pp63-83.
  • Comma A, Zara C, Godman B, Agusti A, Diogène E, Wettermark B, Haycox A. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Review of Pharmacoeconomics &Outcomes Research, 2009. Vol 9; No 6: pp 569-581.

  • Haycox A, Armand C, Murteira S, Cochran J, François, C. Cost-effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting: An Economic Markov Model Evaluation. Drugs &Aging, 2009. Vol 26; No 9: pp791-801.
  • Haycox A. Optimizing Decision Making and Resource Allocation in Palliative Care. Journal of Pain and Symptom Management, 2009. Vol 38; No 1: pp45-53.
  • Araszkiewicz A, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare?. Expert Review of Pharmacoeconomics Outcomes &Research, 2008. Vol 8; No 6: pp549-555.
  • Haycox A. Does NICE blight exist and if so, why? Pharmacoeconomics, 2008. Vol 26; No 12: p1.
  • Medina Lara A, Nyanzi Wakholi B, Kasirye A, Munderi P, Watera C, Lalloo DG, Haycox A, Gilks CF, Grosskurth H. Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. AIDS, 2008. Vol 22 (Suppl 1): S123-S130.
  • Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems – A Position Paper. European Journal of Clinical Pharmacology 2008; 64:1137–1138
  • Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Weininger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Pharmacoeconomics Outcomes Research, 2008. Vol 8; No 4: pp357-371.
  • Haycox A, Featherstone R. Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed? Journal of Medical Economics, 2008. Vol 11: pp525-539.
  • Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent National and Regional Drug Reforms in Sweden. Pharmacoeconomics, 2008. Vol 26; No 7: pp537-550.
  • Godman B, Haycox A, Schwabe U, Joppi R. Having Your Cake and Eating It. Pharmacoeconomics, 2008. Vol 26; No 2: pp91-98.
  • Haycox, A. When NICE says no! Pharmacoeconomics, 2007. Vol 25; No 12: pp995-996. Editorial.
  • Haycox A, Mujica Mota R, Featherstone R. Evaluating the cost-effectiveness of asthma inhaler systems: an observational study of patients in General Practice in the UK. Journal of Medical Economics, 2007. Vol 10: pp 297-308.
  • Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. Health Technology Assessment. 2007 Jan;11(1):1-90.
  • Dundar, Y., Dodd, S., Dickson, R., Walley, T., Haycox, A., Williamson, PR. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technology Assessment, 2006. Vol 10; 5: pp1-162.
  • Whiting, P., Gupta, R., Burch, J., Mujica Mota, RE., Wright, K., Marson, A., Wieshmann, W., Haycox, A., Kleijnen J., Forbes, C. A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. Health Technology Assessment, 2006. Vol 10; 4: pp1-250.
  • Haycox, A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics, 2005. Vol 23; Suppl 1: pp3-16. Review.
  • Mair, FS., Goldstein, P., May, C., Angus, R., Sheils., Hibbert, D., O’Connor, J., Boland, A., Roberts, C., Haycox, A., Capewell, S. Patient and provider perspectives on home telecare: preliminary results from a randomized controlled trial. Journal of Telemedicine and Telecare, 2005. Vol 11; Suppl 1: pp95-97.
  • Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dundar, Y., Haycox, A., Mujica-Mota, R., Reaney, A., Roberts, D., Williamson, P., Walley, T. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technology Assessment, 2005. Vol 8; iii-iv: 1-242. Review.
  • Allsup, S., Haycox, A., Regan, M., Gosney, M. Is influenza vaccination cost-effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine, 2004. Vol 23(5): 639-645.
  • Hill, RA., Dundar, Y., Bakhai, A., Dickson, R.,Walley, T. (2004). Drug-eluting stents: an early systematic review to inform policy. European Heart Journal, 2004. Vol 25(11): pp902-919.
  • Haycox A. Insulin Aspart: An Evidence-Based Medicine Review. Clinical Drug Investigations, 2004. Vol 24; No 12: pp695-717.
  • Dundar, Y., Boland, A., Strobl, J., Dodd, A., Bagust, A., Haycox, A., Bogg, J., Dickson, R., Walley, T. Newer hypnotic drugs for the management of insomnia: a systematic review and economic analysis. Health Technology Assessment, 2004, June. Vol 8, No 24. Monograph.
  • Hibbert, D., Mair, FS., Angus, RM., May, C., Boland, A., Haycox, A., Roberts, C., Shiels, C., Capewell, S. Lessons from the implementation of a home telecare service. Journal of Telemedicine and Telecare, 2003. Vol 9; Suppl 1: ppS55-56.
  • Walley, T., Duggan, AK., Haycox, AR., Niziiol., CJ. Treatment for newly diagnosed hypertension patterns of prescribing and antihypertensive effectiveness in the UK. Journal of the Royal Society of Medicine, 2003 Nov. Vol 96; No 11: pp525-531.
  • Kumana, CR., Tong, MKL., Li, C-S., Lauder, IJ., Lee, JSK., Kou, M., Walley, T., Haycox, A., Chan, TM. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporine. British Journal of Clinical Pharmacology, 2003. Vol 56; pp 670-678.
  • Strobl, J., Enzer, I., Bagust, A., Haycox, A., Smyth, R., Ashby, D., Walley, T. Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry. Pharmacoepidemiology and Drug Safety, 2003, Sep: Vol 12; No 6: pp 467-473.
  • Boland, A., Haycox, A., Bagust, A., Fitzsimmons, L. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment, 2003. Vol 7: No 36. Monograph.
  • Allsup, S., Gosney, M., Haycox, A., Regan, M. Cost–benefit evaluation of routine influenza immunisation in people 65–74 years of age. Health Technology Assessment, 2003. Vol 7: No 24. Monograph.
  • Boland, A., Dundar, Y., Bagust, A., Haycox, A., Hill, R., Mujica-Mota, R., Walley, T., Dickson, R. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technology Assessment NHS R&D HTA Programme, 2003. Vol 7, No 15. Monograph.
  • Riedler, GF., Haycox, AR., Duggan, AK., Dakin, HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sanguinis, 2003. Vol 85, pp 88-95.
  • Riedler, GF., Haycox, AR., Duggan, AK., Dakin, HA. Solvent-detergent-treated plasma may be cost-effective. Vox Sanguinis, 2003. Vol 84, pp 331-338.
  • Sartain, SA., Maxwell, MJ., Todd, PJ., Jones, KH., Bagust, A., Haycox, A., Bundred, P. Randomised controlled trial comparing an acute paediatric hospital at home scheme with conventional hospital care. Archives of Disease in Childhood, 2002. Vol 87; No 5: pp 371–375.
  • Bagust, A., Haycox, A.., Sartain, SA., Maxwell, MJ., Todd, P. Economic evaluation of an acute paediatric hospital at home clinical trial. Archives of Disease in Childhood, 2002. Vol 87, pp 489-492.

  • Haycox, A., Mitchell, G., Niziol, C., Featherstone, R. Cost-effectiveness of asthma treatment with a breath-actuated metered dose inhaler. Journal of Medical Economics, 2002. Vol 5, pp65-77.
  • Whitten, P., Mair, F., Haycox, A., et al. Systematic review of cost-effectiveness studies of telemedicine interventions. British Medical Journal, 2002. Vol 324, Issue 7351, pp1434-1437.
  • Mair, F., Boland, A., Angus, R., Haycox, A., et al. A randomised controlled trial of home telecare. Journal of Telemedicine &Telecare, 2002. Vol 8, Suppl 2, pp58-60.
  • Hughes, DA., Bagust, A., Haycox, A., Walley, T. Accounting for non-compliance in pharmacoeconomic evaluations. Pharmacoeconomics, 2001. Vol 19, No. 12, pp1185-1197.
  • McWilliams, RG., Martin, J., White, D., Gould, DA., Rowlands, PC., Haycox, A., Brennan, J., Gilling-Smith, GL., Harris, PL. Detection of Endoleak with enhanced ultrasound imaging: Comparison with biphasic computed tomography. Journal of Endovascular Therapy, 2002. Vol 9, Issue 2, pp170-179.
  • Sartain, S., Maxwell, MJ., Todd, P., Haycox, A., Bundred, P. Users’ views on hospital and home care for acute illness in childhood. Health and Social Care in the Community, 2001. Vol 9, Issue 2, pp108-117.
  • Haycox, A., Howard, S., Partridge, A., Wright, T. A comparison of evidence and practice in the treatment of constipation. Journal of Medical Economics, 2001. Vol 4, pp91-98.
  • Allsup, S., Gosney, M., Regan, M., Haycox, A., Fear, S., Johnstone, F. Side-effects of influenza vaccination in healthy older people. A randomised single-blind placebo-controlled trial. Gerontology, 2001. Vol 47, Issue 6, pp311-314.
  • McDonald, R., Haycox, A., Walley, T. The impact of health economics on healthcare delivery: The health economists perspective. Pharmacoeconomics, 2001. Vol 19, Issue 8, pp803-809.

  • Hughes, DA., Bagust, A., Haycox, A., Walley, T. The Impact of Non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Economics, 2001. Vol 10, Part 7, pp601-615.
  • Harris, R., Haycox, A. The Role of Team Dentistry in Improving Access to Dental Care in the U.K. British Dental Journal, 2001. Vol 190, Issue 7, pp353-356.
  • Walley, T., Earl-Slater, A., Haycox, A., Bagust, A. An Integrated National Pharmaceutical Policy for the U.K. British Medical Journal, 2000. Vol 321, No. 7275, pp1523-1526.
  • Mair, F., Haycox, A., May, C., Williams, T. A review of Telemedicine cost-effectiveness studies. Journal of Telemedicine and Telecare, 2000. Vol 6, Suppl 1, S38-40.
  • Haycox, A., Einarson, T., Eggleston, A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the domestic/international gastroenterology surveillance survey (DIGEST). Scandinavian Journal of Gastroenterology, 1999. Vol 34, Suppl 231, pp38-47.
  • Haycox, A. Commentary on hospital at home papers, Evidence-Based Health Care, 1999. Vol 3, No. 3, pp64-69.
  • Bagust, A., Roberts, BL., Haycox, A. The additional cost of obesity to the health service and the potential for resource savings from effective interventions. European Journal of Public Health, 1999. Vol 9, No. 4, pp258-264.
  • Roberts, L., Haycox, A. Obesity. About the size of it. Health Service Journal, 1999. Vol 109, No. 5662, pp28-29.
  • Haycox, A., Unsworth, L., Allen, K., Hodgson, R., Lewis, M., Boardman, A. The North Staffordshire community beds study. Longitudinal evaluation of psychiatric inpatient units attached to Community Mental Health Centres. 2: Impact on costs and resource use. British Journal of Psychiatry, 1999. Vol 175, pp79-86.

  • Haycox, A., Bagust, A., Walley, T. Clinical guidelines - the hidden costs. British Medical Journal, 1999. Vol 318, No. 7180, pp391-393.
  • Nicholson, DA., Haycox, A., Kay, CL., Rate, A., Attwood, S., Bancewicz, J. The cost effectiveness of metal oesophageal stenting in malignant disease compared with conventional therapy. Clinical Radiology, 1999. Vol 54, No. 4, pp212-215.
  • Humphrey, K., Cork, MJ., Haycox, A. A retrospective, cost effectiveness analysis of the treatment of onychomycosis in general practice. British Journal of Dermatology, 1998. Vol 139, No. 4, pp660-664.
  • Haycox, A., Lombard, M., Neoptolemas, J., Walley, T. Review Article: Current treatment and optimal patient management in pancreatic cancer. Alimentary Pharmacology and Therapeutics, 1998. Vol 12, No.10, pp949-964.
  • Haycox, A., Lombard, M., Neoptolemas, J., Walley, T. Review Article: Current practice and future perspectives in detection and diagnosis of pancreatic cancer. Alimentary Pharmacology and Therapeutics, 1998. Vol 12, No. 10, pp937-948.
  • Haycox, A., Dubois, D., Butterworth, M. Customising an international disease management model to the needs of individual countries: application to upper gastrointestinal disease. Pharmacoeconomics, 1998. Vol 14, Suppl 2, pp39-56.

  • Haycox, A., Butterworth, M., Walley, T., Barton, S. Development of an economic model for the management of upper gastrointestinal disease in primary care: preliminary findings. Pharmacoeconomics, 1998. Vol 14, Suppl, pp11-23.
  • Eggleston, A., Wigerinck, A., Huijghebgert, S., Dubois, D., Haycox, A. Cost-effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. GUT, 1998. Vol 42, No. 1, pp13-16.
  • Haycox, A., Walley, T., Barton, S. The use of health economics to support clinical decision making in gastroenterology. Gastroenterology International, 1997. Vol 10, No. 2, pp1-3.
  • Haycox, A., Drummond, M., Walley, T. Pharmacoeconomics: integrating economic evaluation into clinical trials. British Journal of Clinical Pharmacology, 1997. Vol 43, No. 6, pp559-562.
  • Walley, T., Haycox, A., Barton, S. Drug rationing in the UK NHS: current status and future prospects. Pharmacoeconomics, 1997. Vol 12, No. 3, pp339-350.
  • Haycox, A., Walley, T. Pharmacoeconomics: evaluating the evaluators. British Journal of Clinical Pharmacology, 1997. Vol 43, No. 5, pp451-456.

  • Walley, T., Haycox, A. Pharmacoeconomics: basic concepts and terminology. British Journal of Clinical Pharmacology, 1997. Vol 43, No. 4, pp343-348.
  • Haycox, A. ‘mit managementplan gezielt gegen oberbauchbeschwerden (using a management plan to tackle upper gastric disease)’. Internist, Berlin, 1996. Vol 37, No. 12, pp1-4.
  • Haycox, A. ‘The role of outcomes research in upper gastrointestinal disease’. Motility, 1996. Vol. 36, pp12-14.
  • Haycox, A. ‘Management of dyspepsia. Management plan aimed at prevention of upper abdominal complaints’. Internist (Berl.), 1996. Vol 37, No. 12, pp1-4 (In German).
  • Mucklow, JC., Haycox, A., Wood, KMG., Jones, PW., Green, JRB. ‘Cost effectiveness management of dyspepsia’. British Journal of Medical Economics, 1996. Vol 10, No 2, pp119-128.
  • Haycox, A., Duggan, AK. ‘Optimising the future developments of dialysis service in the UK’. British Journal of Medical Economics, 1996. Vol 10, No.1, pp27-35.
  • Krupa, BS., Duggan, AK., Haycox, A. ‘Costing renal service provision - The Shrewsbury Renal Model’. British Journal of Medical Economics, 1996. Vol 10, No.1, pp15-26.
  • Haycox. A., Jones, D. ‘The cost effectiveness of renal provision in the NHS’. Journal of Management in Medicine, 1996. Vol 10, No 1, pp6-15.
  • Jones, DL., Haycox A. “Information requirements underlying medical decision-making in the diagnosis and early management of spontaneous subarachnoid haemorrhage’. Topics in Health Information Management, 1995. Vol 16, No 2, pp 29-39.
  • Peers, EM., Scrimgeour, AC., Haycox, A. ’Cost Containment in CAPD Patients with Ultrafiltration Failure’. Clinical Drug Investigation, 1995. Vol 10, No. 1, pp53–58.
  • Haycox, A. ‘A Methodology for Estimating the Costs and Benefits of Health Promotion’. Health Promotion International, 1994. Vol 9, No. 1, pp5–11.
  • Twomey, J., Tomkins, J., Theaker, T., Haycox, A. ‘Public Sector Health Resources and Management: The Evaluation of Health Promotion Expenditure’. Public Money and Management, 1993. Vol 13, No. 1, pp1-4.
  • Quigley, C., Kaczmarski, EB., Jones, DM., Haycox, AR. ‘Haemophilus Influenza Type B Disease in North West England’. Journal of Infection, 1993. Vol 26, No. 2, pp215-220.
  • St Leger, S., Rowsell, K., Standing, V., Haycox, A. ‘Evaluation of Pharmaceutical Innovation: challenges and opportunities arising from the reforms to the National Health Service in the United Kingdom’. Pharmacoeconomics, 1992. Vol 1, No. 5, pp306-311.
  • Standing, V., Walsworth-Bell, J., Allen, D., Haycox, A., Ackrill, P., Gokal, R., Twomey, J. ‘Drug Innovation, Cost Effectiveness and Management: The Case of Erythropoietin’. Journal of Management in Medicine, 1989. Vol 4, No. 3, pp189-194.
  • Cribb, A., Haycox, A. ‘Economic Analysis in the Evaluation of Health Promotion’. Community Medicine, 1989. Vol 11, No. 4, pp299-305.
  • Johnes, G., Haycox, A. ‘Ward Size and Costs: A study of a Large Mental Handicap Hospital’. Mental Handicap, 1986. Vol 14, pp137–139.
  • Johnes, G., Haycox, A. ‘Cost Structures in a Large Hospital for the Mentally Handicapped’. Social Science and Medicine, 1986. Vol 22, No. 6, pp605–610.

  • Training

    LHE offers a range of training courses in health economics topics to help support best practice and evidence-based decision making. Our training programmes are offered onsite at the University of Liverpool which offers world-class facilities. In addition, we offer these training courses at your own site and through distance learning if preferred.

    LHE provide courses from the foundations of health economics to contemporary issues within decision-making. The training courses can be tailored to meet the requirements of the client and offer an open forum for debate. LHE training courses offered by LHE and the Department of Economics at the University of Liverpool range from:

    • Intensive 1-5 day Training Workshops
    • Undergraduate module in Health Economics
    • Distance learning postgraduate degree in Health Economics and Management MSc/PGDip/PGCert (FT/PT)

    For more details with respect to any health economics training course, please contact us. Further details about the postgraduate course offered are provided below:

    Health Economics and Management MSc/PGDip/PGCert (FT/PT)

    Overview

    The University of Liverpool’s online postgraduate programme in Health Economics and Management (MSc/PGDip/PGCert) is designed for health professionals looking to develop their capacity to engage critically with economic, financial and management challenges they confront in healthcare. As the demand for more advanced and expensive healthcare puts increasing pressure on policy decision makers and healthcare industry managers, the necessity for expertise in health economics continues to grow.

    The principal aim of the course is to develop an analytical skill-base required to evaluate and improve both the efficacy and effectiveness of healthcare systems throughout the world. In addition, the aim is to develop a deeper understanding of current and innovative methods to support and inform evidence-based healthcare decision making.

    The programme seeks to meet both the needs of employers and employees, to develop capacity in the economic evaluation of health services, by transferring expertise and practical knowledge. The postgraduate programme in Health Economics and Management (MSc/PGDip/PGCert) offers health professionals with an opportunity to develop highly desirable skills and gain a widely recognised qualification from a leading UK university.

    Why choose this programme?

    • You will gain new skills and knowledge that you can apply immediately in your current role, so you can start making a difference from day one
    • The curriculum is designed from an international health perspective
    • You will have the opportunity to interact and collaborate with peers from around the world, adding to the global relevance of this online programme
    • The online programme is taught by respected professionals with wide ranging practical experience across a number of fields within Health Economics and Management
    • Designed with input from industry experts and employers, the programme has a firm healthcare focus, blending theory and practice, and covering innovative concepts in the field
    • You will study within a blended learning environment, benefiting from a combination of online and face-to-face support
    • You will benefit from a personalised support programme, helping to keep you inspired, motivated and on track
    • You will be gaining a qualification from a globally respected university and AACSB-accredited management school

    Module details

    Our postgraduate programme in Health Economics and Management comprises of seven core modules and an economic evaluation project. The programme is designed to be flexible around the student and the number modules which are undertaken is optional.

    In addition, there is an option to complete an economic evaluation project. A topic is refined in conjunction with your personal Project Advisor, who will be there to support you throughout the research and writing process. The modules include:

    • Economics & Resource Allocation
    • Health Economics
    • Advanced Health Economics
    • Economic Modelling
    • Public Governance
    • Financial Accountability
    • Economic Evaluation Project
    The postgraduate programme in Health Economics and Management develops your ability to engage critically with On completion of 3 modules a Postgraduate Certificate will be awarded, on completion of 6 modules a Postgraduate Diploma will be awarded and on completion of the 7 modules including the Economic Evaluation Project a Master of Science in Health Economics and Management will be awarded.

    Our MSc/PGDip/PGCert Health Economics and Management programme is covered by accreditation from The Association to Advance Collegiate Schools of Business (AACSB) – the longest serving global accrediting body for business schools. Much sought-after, AACSB Accreditation is awarded to less than 5% of the world’s business and management schools.

    Careers

    The postgraduate programme in Health Economics and Management develops your ability to engage critically with economic, financial and management challenges confronted in the healthcare.

    Our postgraduate programme in Health Economics and Management is designed to prepare you for a successful career as a health professional and inaugurate positive change within the healthcare sector. Furthermore, the programme prepares you for career opportunities in a wide range of areas such as:

    • Policy analysis in the healthcare industry
    • Healthcare organisations and governmental bodies
    • Non-governmental organisations
    • Economic evaluation of products within the pharmaceutical industry
    • Health related consultancies
    • Teaching and academic research in academic institutions

    Entry requirements

    Our postgraduate programme in Health Economics and Management is aimed at both graduates and non-graduates looking to further their careers with further training. Both educational qualifications and work experience are taken into consideration when you apply to the University.

    In general, you will be expected to have a bachelors degree (lower second or equivalent minimum) from an accredited college or university or a degree from a recognised institution comparable and/or equivalent to a British honours degree.

    Work experience will also be important and we will be guided by the assessment of the potential of students offered by their sponsoring employers. Applicants who do not directly meet the educational requirements will be evaluated on an individual basis, taking into account vocational and professional qualifications, and relevant working experience.

    The courses and learning materials are provided in English. It is therefore a minimum requirement that candidates have a working proficiency in English.

    Contact

    Contact Details

    Please contact us at LHE to find out how we can help:

    Liverpool Health Economics
    Management School,
    University of Liverpool,
    Chatham Street,
    Liverpool
    L69 7ZH,
    United Kingdom.

    LHE business hours are 9:00 to 18:00.

    Phone: +44 (0)151 795 3612
    Email: ahay@liv.ac.uk

    Liverpool is located just over two hours from London by train and has good transport links to the rest of the UK. Both Liverpool and Manchester international airports are located nearby and provide a gateway to the rest of the world. The LHE team are located within the University of Liverpool Management School and the building is easily accessible via public transport.


    Further Information

    LHE has world-class facilities accessible on-site for conducting meetings and seminars. Our campus is a memorable place to visit, with its beautiful historic buildings alongside ultra-modern institutes, teaching laboratories and residences.

    The University of Liverpool is one of the great centres of research, knowledge and innovation and our pioneering reputation attracts students, experts and partners from around the world. Through our research, teaching and collaborations we seek to be life changing and world shaping. We continue to pursue novel interdisciplinary research that helps mankind understand and solve the problems it faces.

    Liverpool has been home to explorers and revolutionaries for over 800 years. Their pioneering spirit is alive in the city and inspires our university. Our university is everywhere, from our Chinese joint venture University to our Arctic research stations, American exchanges to the Internet home of our online programmes.

    Slogan Uol Logo